Pharmacologic treatment in patients with COVID-19: an integrative review
Introduction: Today more than ever human health has been compromised; humanity is suffering from the invasion of the SARS-CoV-2 coronavirus, which has exposed the world to the worst health emergency in this century. Although the scientific community and global health systems are joining efforts in t...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , , , , |
|---|---|
| Μορφή: | Online |
| Γλώσσα: | spa eng |
| Έκδοση: |
Universidad de Sonora
2021
|
| Διαθέσιμο Online: | https://sanus.unison.mx/index.php/Sanus/article/view/250 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|
| id |
oai:https:--sanus.unison.mx:article-250 |
|---|---|
| record_format |
ojs |
| institution |
Sanus |
| collection |
OJS |
| language |
spa eng |
| format |
Online |
| author |
Vargas, María Rubi Melendrez-Arango, Esthela Carolina Durán-Aguirre, María Lorena Quiñones Lucero, Lourdes Peralta-Peña, Sandra Lidia |
| spellingShingle |
Vargas, María Rubi Melendrez-Arango, Esthela Carolina Durán-Aguirre, María Lorena Quiñones Lucero, Lourdes Peralta-Peña, Sandra Lidia Pharmacologic treatment in patients with COVID-19: an integrative review |
| author_facet |
Vargas, María Rubi Melendrez-Arango, Esthela Carolina Durán-Aguirre, María Lorena Quiñones Lucero, Lourdes Peralta-Peña, Sandra Lidia |
| author_sort |
Vargas, María Rubi |
| title |
Pharmacologic treatment in patients with COVID-19: an integrative review |
| title_short |
Pharmacologic treatment in patients with COVID-19: an integrative review |
| title_full |
Pharmacologic treatment in patients with COVID-19: an integrative review |
| title_fullStr |
Pharmacologic treatment in patients with COVID-19: an integrative review |
| title_full_unstemmed |
Pharmacologic treatment in patients with COVID-19: an integrative review |
| title_sort |
pharmacologic treatment in patients with covid-19: an integrative review |
| description |
Introduction: Today more than ever human health has been compromised; humanity is suffering from the invasion of the SARS-CoV-2 coronavirus, which has exposed the world to the worst health emergency in this century. Although the scientific community and global health systems are joining efforts in the search for a definitive treatment, to date it is recognized that the therapy is aimed at mitigating the symptoms. Objective: Identify scientific evidence on pharmacological treatment for patients with COVID-19. Methodology: An integrative review of literature published from December 2019 to October 2020, in the following information systems Clinical Key, Dialnet, EBSCO Host and Scopus was performed using the descriptors Coronavirus Infections, COVID-19, Drug therapy, and pharmacological treatment. The selection criteria were quantitative research articles of any type of design, in English and Spanish, available in full text, obtaining a sample of 24 articles. Results: Most of the studies were integrative reviews with a percentage of 66.6 and clinical or in vitro trials with a percentage of 12.5. Nine drugs of major use in COVID-19 were identified in the drug therapy, that is, Hydroxychloroquine/Chloroquine, Lopinavir/Ritonavir, Remdesivir, Azithromycin, Ivermectin, Tocilizumab and Dexamethasone. However, According to the scientific evidence only four drugs showed significant effectiveness. Conclusions: Remdesivir demonstrated greater effectiveness and safety during the treatment, and Tocilizumab and Dexamethasone showed favorable results. Nevertheless, the results are not conclusive. The authors pointed out that so far is not possible to conclude there are treatments that effectively fight COVID-19. |
| publisher |
Universidad de Sonora |
| publishDate |
2021 |
| url |
https://sanus.unison.mx/index.php/Sanus/article/view/250 |
| work_keys_str_mv |
AT vargasmariarubi pharmacologictreatmentinpatientswithcovid19anintegrativereview AT melendrezarangoesthelacarolina pharmacologictreatmentinpatientswithcovid19anintegrativereview AT duranaguirremarialorena pharmacologictreatmentinpatientswithcovid19anintegrativereview AT quinoneslucerolourdes pharmacologictreatmentinpatientswithcovid19anintegrativereview AT peraltapenasandralidia pharmacologictreatmentinpatientswithcovid19anintegrativereview AT vargasmariarubi tratamientofarmacologicoenpacientesconcovid19unarevisionintegradora AT melendrezarangoesthelacarolina tratamientofarmacologicoenpacientesconcovid19unarevisionintegradora AT duranaguirremarialorena tratamientofarmacologicoenpacientesconcovid19unarevisionintegradora AT quinoneslucerolourdes tratamientofarmacologicoenpacientesconcovid19unarevisionintegradora AT peraltapenasandralidia tratamientofarmacologicoenpacientesconcovid19unarevisionintegradora AT vargasmariarubi tratamentofarmacologicoempacientescomcovid19umarevisaointegrativa AT melendrezarangoesthelacarolina tratamentofarmacologicoempacientescomcovid19umarevisaointegrativa AT duranaguirremarialorena tratamentofarmacologicoempacientescomcovid19umarevisaointegrativa AT quinoneslucerolourdes tratamentofarmacologicoempacientescomcovid19umarevisaointegrativa AT peraltapenasandralidia tratamentofarmacologicoempacientescomcovid19umarevisaointegrativa |
| _version_ |
1756584911500738560 |
| spelling |
oai:https:--sanus.unison.mx:article-2502022-01-08T12:19:55Z Pharmacologic treatment in patients with COVID-19: an integrative review Tratamiento farmacológico en pacientes con COVID-19: una revisión integradora Tratamento farmacológico em pacientes com COVID-19: uma revisão integrativa Vargas, María Rubi Melendrez-Arango, Esthela Carolina Durán-Aguirre, María Lorena Quiñones Lucero, Lourdes Peralta-Peña, Sandra Lidia COVID-19, infecciones por coronavirus, tratamiento farmacológico, COVID-19, Drug therapy Introduction: Today more than ever human health has been compromised; humanity is suffering from the invasion of the SARS-CoV-2 coronavirus, which has exposed the world to the worst health emergency in this century. Although the scientific community and global health systems are joining efforts in the search for a definitive treatment, to date it is recognized that the therapy is aimed at mitigating the symptoms. Objective: Identify scientific evidence on pharmacological treatment for patients with COVID-19. Methodology: An integrative review of literature published from December 2019 to October 2020, in the following information systems Clinical Key, Dialnet, EBSCO Host and Scopus was performed using the descriptors Coronavirus Infections, COVID-19, Drug therapy, and pharmacological treatment. The selection criteria were quantitative research articles of any type of design, in English and Spanish, available in full text, obtaining a sample of 24 articles. Results: Most of the studies were integrative reviews with a percentage of 66.6 and clinical or in vitro trials with a percentage of 12.5. Nine drugs of major use in COVID-19 were identified in the drug therapy, that is, Hydroxychloroquine/Chloroquine, Lopinavir/Ritonavir, Remdesivir, Azithromycin, Ivermectin, Tocilizumab and Dexamethasone. However, According to the scientific evidence only four drugs showed significant effectiveness. Conclusions: Remdesivir demonstrated greater effectiveness and safety during the treatment, and Tocilizumab and Dexamethasone showed favorable results. Nevertheless, the results are not conclusive. The authors pointed out that so far is not possible to conclude there are treatments that effectively fight COVID-19. Introducción: La salud hoy más que nunca ha sido vulnerada, la humanidad está sufriendo por la invasión del coronavirus SARS-CoV-2, que ha expuesto al mundo a la peor emergencia sanitaria en este siglo. La comunidad científica y los sistemas de salud global conjuntan esfuerzos en la búsqueda de un tratamiento definitivo, a la fecha se reconoce que la terapia está dirigida a mitigar los síntomas. Objetivo: Identificar las evidencias científicas sobre el tratamiento farmacológico en los pacientes con COVID-19. Metodología: Se realizó una revisión integradora de la literatura publicada de diciembre 2019 a octubre 2020, en los sistemas de información Clinical Key, Dialnet, EBSCO Host y Scopus, mediante los descriptores Coronavirus Infections, COVID-19, Drug therapy, tratamiento farmacológico. Los criterios de selección fueron artículos de investigación cuantitativa de cualquier tipo de diseño, en inglés y español disponibles a texto completo, obteniéndose una muestra de 24 artículos. Resultados: La mayoría de los estudios fueron revisiones integrativas con 66.6% y ensayos clínicos o in vitro con 12.5%. Se identificaron en la terapia farmacológica nueve medicamentos de mayor uso en COVID-19: Hidroxicloroquina/cloroquina, lopinavir/ritonavir, remdesivir, azitromicina, ivermectina, tocilizumab y dexametasona, no obstante, solo cuatro fármacos mostraron efectividad significativa según la evidencia científica. Conclusiones: remdesivir demostró mayor efectividad y seguridad en el tratamiento, tocilizumab y dexametasona mostraron resultados favorables, sin embargo, los resultados no son contundentes. Los autores señalan que aún no es posible afirmar que se dispone de tratamientos que combata la COVID-19 efectivamente. Introdução: Hoje, mais do que nunca, a saúde humana foi comprometida; a humanidade está sofrendo com a invasão do coronavírus SARS-CoV-2,que expôs o mundo à pior emergência sanitária deste século. Embora a comunidade científica e os sistemas globais de saúde estejam unindo esforços na busca por um tratamento definitivo, até o momento é reconhecido que a terapia visa mitigar os sintomas. Identificar evidências científicas sobre o tratamento farmacológico de pacientes com COVID-19.Objetivo: Identificar evidências científicas sobre o tratamento farmacológico para pacientes com COVID-19.Metodologia: Foi realizada uma revisão integrativa da literatura publicada de dezembro de 2019 a outubro de 2020,nos seguintes sistemas de informação Clinical Key,Dialnet,EBSCO Host e Scopus utilizando os descritores Coronavirus Infections,COVID-19,Drug therapy and pharmacological treatment. Os critérios de seleção foram artigos de pesquisa quantitativa,de qualquer tipo de delineamento,nos idiomas inglês e espanhol,disponíveis na íntegra, obtendo-se uma amostra de 24 artigos.Resultados: A maioria dos estudos foram revisões integrativas com percentual de 66,6 e ensaios clínicos ou in vitro com percentual de 12,5. Nove medicamentos de maior uso no COVID-19 foram identificados na terapia medicamentosa,ou seja,Hidroxicloroquina/Cloroquina,Lopinavir/Ritonavir,Remdesivir, Azitromicina,Ivermectina,Tocilizumabe e Dexametasona. No entanto, de acordo com as evidências científicas, apenas quatro medicamentos mostraram eficácia significativa. Conclusões: De acordo com as evidências científicas, apenas quatro medicamentos mostraram eficácia significativa. Conclusões: Remdesivir demonstrou maior eficácia e segurança durante o tratamento, e Tocilizumabe e Dexametasona apresentaram resultados favoráveis. No entanto, os resultados não são conclusivos. Os autores apontaram que até o momento não é possível concluir que existam tratamentos que combatam efetivamente o COVID-19. Universidad de Sonora 2021-12-31 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Artículo evaluado por pares INTRODUCCIÓN En el contexto internacional existe un consenso sobre la situación compleja que guarda la salud hoy día, misma que se ha intensificado por el impacto de la pandemia COVID-19 que ha expuesto al mundo a la peor emergencia sanitaria en este sig application/pdf application/pdf text/xml https://sanus.unison.mx/index.php/Sanus/article/view/250 10.36789/revsanus.vi1.250 SANUS; Vol. 6 (2021): January-December; e250 SANUS; Vol. 6 (2021): Enero-Diciembre; e250 SANUS; v. 6 (2021): Enero-Diciembre; e250 2448-6094 spa eng https://sanus.unison.mx/index.php/Sanus/article/view/250/292 https://sanus.unison.mx/index.php/Sanus/article/view/250/293 https://sanus.unison.mx/index.php/Sanus/article/view/250/313 Derechos de autor 2021 https://creativecommons.org/licenses/by-nc-nd/4.0 |
